Market Trends of PD-1 And PD-L1 Inhibitors Industry
PD-1 Inhibitors Segment is Expected to Witness Significant Growth Over the Forecast Period
- PD-1 (programmed cell death protein 1) inhibitors are a class of immunotherapy drugs used to treat cancer. PD-1 is a protein found on the surface of specific immune cells called T cells. It helps regulate the immune response by inhibiting T cells from attacking normal cells in the body. PD-1 inhibitors have shown significant clinical benefits in several types of cancer and have revolutionized the treatment landscape, particularly for patients with advanced or metastatic disease. They can induce durable responses and have demonstrated improved overall survival rates compared to traditional chemotherapy in some cases.
- Some well-known benefits of PD-1 inhibitors include enhanced immune response, improved survival rate, reduced toxicity, and potential long-lasting response. PD-1 inhibitors can be combined with other cancer treatments, such as chemotherapy, radiation therapy, targeted therapy, or other immunotherapies. Combinations of PD-1 inhibitors with other agents have shown synergistic effects, leading to improved response rates and patient outcomes. PD-1 inhibitors have been approved for treating multiple types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, classical Hodgkin lymphoma, urothelial carcinoma, and others. Some of the commonly used PD-1 inhibitors are Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Cemiplimab (Libtayo), among others.
- A study published in ASH publications in November 2022 disclosed the results of an open-label phase 1/2 study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in relapsed or refractory classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment. As per the study, heavily pretreated patients with R/R cHL whose disease progressed after anti-PD-1 therapy showed effective antitumor activity and tolerable safety. Additionally, according to new clinical study results published by the National Institute of Health in August 2022, it was found that adding the immunotherapy medicine pembrolizumab (Keytruda) to chemotherapy can help certain patients with advanced triple-negative breast cancer live longer than if they only got chemotherapy. Such research and development supporting PD-1 inhibitor therapies are anticipated to drive overall market growth.
- Furthermore, significant new drug launches in the PD-1 inhibitors space have been a fuelling factor for the segment's growth. For instance, in January 2023, the Food and Drug Administration (FDA) approved KEYTRUDA (pembrolizumab) as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with Stage IB, II, or IIIA Non-Small Cell Lung Cancer (NSCLC).
- Therefore, with the benefits associated with PD-1 inhibitors and the new launches, the segment is expected to witness robust growth over the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North American is Expected to Hold a Significant Market Share during the Forecast Period
- North America is expected to grow significantly in the PD-1 and PD-L1 inhibitors market over the forecast period due to the growing prevalence of various cancer cases, such as skin cancer, urothelial carcinomas, and lung cancers, in the United States, Canada, and Mexico, among other countries in the region. Additionally, product launches and investments are the other factors that drive the overall market's growth in the region.
- The growing burden of cancer in the United States is expected to boost the demand for PD-1 and PD-L1 inhibitors, thereby boosting regional market growth. For instance, according to the statistics published by the American Cancer Society (ACS) in 2023, the estimated incidence of cancer cases increased from 1.91 million in 2021 to 1.96 million in 2023, an increase of more than 60 thousand cases in just two years, demonstrating a rapid growth in the cancer cases within the country.
- Furthermore, increasing investment in cancer research is one of the key factors in market growth. For instance, the Consolidated Appropriations Act 2022 allocated nearly USD 6,900 million to the National Cancer Institute (NCI), a USD 353 million net increase over FY2021. The Cancer Moonshot received USD 194 million in funding in FY2022, and the Childhood Cancer Data Initiative received USD 50 million. The allocation of USD 6.9 billion to the National Cancer Institute (NCI) allows for more research and development activities, leading to advancements in understanding the mechanisms and developing more effective inhibitory mechanisms. The Cancer Moonshot and Childhood Cancer Data Initiative funding supports research and clinical trials, which can result in expanded indications and regulatory approvals. Ultimately, this is expected to increase the investment and patient access to PD-1 and PD-L1 inhibitors, fostering market growth during the analysis period.
- Moreover, increasing product launches in the region is expected to increase the availability of the drugs, thereby boosting market growth. For instance, in March 2023, the US FDA approved Zynyz(retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). Similarly, in September 2022, the US-FDA approved durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). Thus, owing to the rising R&D and the presence of better healthcare infrastructure, along with the high prevalence of cancer in the region, the market is expected to witness a significant growth rate over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
